on behalf of the American Thoracic Society Committee on Spirometry in the Occupational Setting
Methods: Issues that previous American Thoracic Society spirometry statements did not adequately address with respect to the workplace were identified for systematic review. Medline 1950-2012 and Embase 1980-2012 were searched for evidence related to the following: training for spirometry technicians; testing posture; appropriate reference values to use for Asians in North America; and interpretative strategies for analyzing longitudinal change in lung function. The evidence was reviewed and technical recommendations were developed.
Results: Spirometry performed in the work setting should be part of a comprehensive workplace respiratory health program. Effective technician training and feedback can improve the quality of spirometry testing. Posture-related changes in FEV 1 and FVC, although small, may impact interpretation, so testing posture should be kept consistent and documented on repeat testing. Until North American Asian-specific equations are developed, applying a correction factor of 0.88 to white reference values is considered reasonable when testing Asian American individuals in North America. Current spirometry should be compared with previous tests. Excessive loss in FEV 1 over time should be evaluated using either a percentage decline (15% plus loss expected due to aging) or one of the other approaches discussed, taking into consideration testing variability, worker exposures, symptoms, and other clinical information. 
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Introduction
The purpose of this document is to address selected aspects of spirometry performed as part of a workplace respiratory health program. The most recent ATS/ERS standards address spirometry performance and interpretation (1-3), but do not focus on issues specifically related to the work setting. Other organizations and governmental agencies have published documents that address certain aspects related to spirometry in the work setting, such as the American College of Occupational and Environmental Medicine (ACOEM) (4) (5) (6) , the Occupational Safety and Health Administration (OSHA) (7) , and the National Institute for Occupational Safety and Health (NIOSH) (8) . However, an ATS document that uses systematic literature reviews to provide additional guidance for the work setting is needed. Spirometry that is performed as part of a workplace spirometry program differs from clinical diagnostic spirometry in several key respects, including its purpose, patient-healthcare provider-employer relationships, and its role in individual and workplace decision making, as detailed in Table 1 . Four issues thought to be inadequately addressed in previous ATS spirometry statements were selected for evidence-based review and recommendations: (1) technician training; (2) spirometry test posture; (3) reference values for Asians in North America and Europe; and (4) evaluation of spirometry over time. Other important areas, such as quality control considerations and test interpretation, are discussed in detail in other recent documents (2, 3, (6) (7) (8) . The intended audience is occupational health, primary care and pulmonary clinicians, occupational and public health professionals, and other personnel involved in worker health and safety.
Methods
The project co-chairs were selected by the leadership of the Environmental and Occupational Health Assembly on the basis of their experience in group leadership and occupational medicine. Committee members were selected based upon their expertise in pulmonary medicine, occupational health, and/or spirometry. Potential conflicts of interest among the chairs and committee members were disclosed, vetted, and managed according to the policies and procedures of the ATS.
Issues identified for detailed evidencebased review of the literature were: (1) optimal training for technicians performing spirometry; (2) 
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in the systematic reviews that were based on work populations, the committee also considered indirect evidence from studies conducted in alternative settings or with nonoccupational populations. Additional relevant papers identified by committee members were included.
The full committee discussed the results in a series of meetings. Committee members were then divided into groups and assigned to write a portion of the document. The co-chairs collated and edited the contributions from each group into a single document, which was then reviewed by the full committee. After several cycles of review, comments, and revisions, the document was approved by all members of the committee for submission.
Technician Training
The importance of technician training and feedback in assuring high-quality spirometry testing is widely recognized. In the United States, OSHA requires that technicians performing spirometry for certain occupational indications complete a training course (9) (10) (11) . European countries are also implementing standards for training and qualification of technicians (12) . ATS/ERS and ACOEM note the importance of training and recommend training similar to a NIOSH-approved spirometry course (3, 4, 6) , and refresher training at 3-5 years and 5-year intervals, respectively (3, 4, 6) . However, the specific components and timing of a training program that are most effective are not clear. A systematic review of the literature was performed to identify evidence related to the impact of technician training on spirometry quality in the workplace. The review identified 22 relevant papers: 2 studies of workers exposed to the World Trade Center disaster and 20 nonoccupational studies, summarized in Table E1 in the online supplement .
The largest body of literature supporting technician training and feedback consists of observational reports from large spirometry programs, where the combination of initial training, refresher training, electronic feedback from spirometers, and on-going test quality review and feedback have been used together to achieve high levels of acceptable spirometry tests and technician performance. Examples include spirometry programs for general populations (18, 21, 22) , the elderly (13), and World Trade Center surveillance (19, 20) .
More limited evidence supports the effectiveness of individual components of training and feedback (27) . Several studies support the usefulness of refresher training and providing technicians with feedback (18) . Assigning spirometry test quality grades may also be helpful in providing feedback (20) . However, the optimal frequency for refresher training remains unclear.
Recommendations for specific content of training courses have been based on professional judgment. ATS/ERS and ACOEM both recommend training similar to the NIOSH-approved spirometry training, 2-and 3-day courses that include didactic training in the fundamentals of spirometry and hands-on training (3, 4, 6) . Approaches to optimizing spirometry quality, including equipment considerations, technician training, and testing technique are summarized in Table 2 and addressed in greater detail in several recent documents (1, 2, 4, 6, 12) .
Recommendation
Technicians should undergo initial practical training and refresher courses to maintain their skills. Technicians should also receive on-going feedback about the quality of tests that they perform, and how to correct problems in test performance.
Posture during Spirometry
The 2005 ATS/ERS guideline (3) recommends performing spirometry in the standing or sitting test posture, whereas ACOEM (4) recommends that testing be conducted standing, unless workers have experienced problems with fainting. To clarify whether standing versus sitting impacts spirometry results in the workplace, a systematic review of the medical literature was performed. The search identified seven relevant studies (see Table E2 ) (35) (36) (37) (38) (39) (40) (41) , although none were performed in an occupational setting. Two studies found significant postural effects. Standing values of the FEV 1 and/or FVC exceeded sitting values by 0.04-0.07 L (37, 41) . Studies comparing these postures 
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have also reported no significant differences in FEV 1 and/or FVC (35, 37, 40) . Although small, changes in FEV 1 and FVC related to posture may be significant when evaluating spirometry longitudinally. No published studies were identified that reported safety concerns with standing versus sitting.
Recommendation
Standing or sitting test posture can be used, but the same posture should be used when possible on repeat testing, and this should be documented. The rationale is that posture-related changes in FEV 1 and FVC, although small, may significantly impact spirometry interpretation.
Reference Values Identifying Individuals with Abnormal Spirometry, Lower Limit of Normal
Determining what constitutes an abnormal versus a normal spirometry result is particularly important when spirometry is performed related to the workplace. In addition to prompting further evaluation of a worker and workplace exposures, an "abnormal" spirometry result can also impact a worker's job (e.g., determining job placement). The ATS/ERS and ACOEM recommend using the fifth percentile lower limit of normal (LLN) to differentiate normality from abnormality, rather than a fixed value, such as 80% of predicted, for the FEV 1 and FVC, or 0.70 for the observed ratio of FEV 1 /FVC (3, 6) . Because the FEV 1 /FVC ratio declines with age, using a fixed value, such as 0.70, to determine an obstructive defect will result in falsenegative results for younger workers (age 25-45 yr), and false-positive results in older workers (men .45 yr, women .55 yr) (42) . Spirometry values that are below the fifth percentile LLN are considered abnormal, and may reflect a pulmonary problem. However, by definition, 5% of a healthy population will also fall below the fifth percentile LLN. (6) . We conducted an evidence-based systematic review of the literature to determine an appropriate adjustment factor to use for persons of Asian ethnicity in the North American workplace. The review identified seven studies that met inclusion criteria, although they did not specify an occupational setting (see Table E3 ) (45) (46) (47) (48) (49) (50) (51) . FEV 1 and FVC values were, on average, 7-20% lower for Asian Americans compared with reference values for whites in these studies (45) (46) (47) (48) (49) (50) (51) . These findings are consistent with studies performed in Asia-Pacific countries showing generally smaller lung volumes in these populations compared with whites (52, 53) . Analysis of spirometry from 1,068 participants in the Multi-Ethnic Study of Atherosclerosis provides the best current data to approximate a correction factor for Asian-Americans (46) . The authors concluded that a correction factor for Asian-Americans of 0.88 was more appropriate than the previous recommendation of 0.94. The other studies identified were very limited in size (47, 48, 50) , and/or were limited to a specific population (45, 49, 51) . Thus, although normative data on persons of Asian ancestry living in North America and Europe remains limited, a correction factor of 0.88 is considered more appropriate than 0.94.
The reviewed articles also demonstrate the considerable variability within the same racial/ethnic group (e.g., Asians, Hispanics), the limited data on many ethnic groups (e.g., in India, Pakistan), the complexity of identifying appropriate reference values (52) (53) (54) , and the complexities in assigning racial/ethnic groups (55) . Assigning specific correction factors for racial/ethnic groups will become even more complicated in the future as racial/ethnic diversity increases.
Recommendation
Racial or ethnic differences in lung function exist. It is preferable to use specific reference equations (such as NHANES III) that have been developed from studies of certain populations when they are available (3). When such reference equations are not available, however, the use of correction factors is an appropriate interim solution.
As an example, a correction factor of 0.88 may be applied to white subject reference values for FEV 1 and FVC when evaluating Asian populations within North America.
Evaluation of Spirometry over Time
Longitudinal evaluations of periodic spirometry testing may detect excessive lung function loss due to an exposure or underlying condition earlier than using a single spirometry test.
How to evaluate loss of lung function over years has not been directly addressed by the ATS or ERS (3). We performed an evidence-based systematic literature review to identify evidence relevant to the question of how to evaluate excessive decline in lung function in a North American or European working population (see the online supplement). Of the 97 papers selected for full review, 7 met the inclusion criteria, which included longitudinal spirometry (at least three spirometry tests over 5 yr) that was performed in an occupational cohort (with either normal control subjects or a low-exposure group), and incorporated an assessment of variability in FEV 1 decline (see Table E4 ) (57) (58) (59) (60) (61) (62) (63) . Additional papers relevant to assessing longitudinal change in lung function were also considered (see Table E5 ) (64) (65) (66) (67) (68) .
Lung function normally increases during childhood, before reaching a maximum, and then starting to decline, around the age of the mid-20s to mid-30s (43, 65, 66, 69) . A systematic review of the literature identified the typical rate of decline in FEV 1 in nonsmokers as 29 ml/yr (70) . The rate of decline can be affected by occupational exposures, cigarette smoking, AMERICAN THORACIC SOCIETY DOCUMENTS weight gain, general lack of fitness, and sex (51, 66, 69, (71) (72) (73) , and may accelerate in older individuals (62, 65, 66) . More rapid lung function decline, typically about 50-90 ml/yr, has been associated with increased morbidity and mortality from chronic obstructive pulmonary disease and cardiovascular disease, and with increased all-cause mortality (74) (75) (76) (77) (78) .
Assessment of decline in lung function is affected by several factors, including: spirometry technical quality and test variability; testing frequency and duration of follow up; and definition of excessive decline. The primary measurement used to assess longitudinal change should be the FEV 1 , as it is less affected by technical factors than the FVC (3, 6).
Spirometry Testing Quality and Test Variability
As noted previously here, comprehensive spirometry programs should be established so that valid measurements are recorded over time. Even with good programs, spirometer inaccuracy and imprecision and survey biases (unexplained technical changes) may limit the size of the detectable change or contribute extraneous variability to longitudinal measurements (79) . Changes in weight over time should be recorded, since weight gain can contribute to decline in lung function (71, 72, 80, 81) . Maintaining calibration check records and tracking spirometry results for groups of workers over time (e.g., mean FEV 1 , withinperson variation, proportions of high or low values) can help identify ongoing health hazards and also anomalous results possibly resulting from technical issues (60, 78, 82) .
Frequency and Duration of Testing
As length of follow up increases, real decline in pulmonary function becomes easier to distinguish from background measurement variability. The precision of the estimated rate of FEV 1 decline improves with increasing frequency of measurement and duration of follow-up (58, 60, 83) . Because chronic occupational respiratory diseases (such as chronic obstructive pulmonary disease and pneumoconioses) typically develop over many years, spirometry performed less frequently than annually (e.g., every 2-3 yr) should be sufficient to monitor for the development of such diseases (63, 82) . However, for diseases that can develop more rapidly (such as flavoring-related lung disease or occupational asthma), more frequent follow up at intervals of 6 month to 1 year may be appropriate (84) (85) (86) .
Determination of Excessive Decline in FEV 1
Great care is required in determining what constitutes an "excessive" FEV 1 decline when evaluating periodic testing in worker populations. It is important to avoid the consequences of either false-positive or -negative findings. 
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Change in FEV 1 over time in workers can be evaluated using several approaches, summarized in Table 3 . These methods are most effective for evaluating declines in FEV 1 over relatively long time periods (>5 yr). Excessive shorter-term (,5 yr) longitudinal FEV 1 declines have been shown to presage long-term losses (60, 87) , but can be difficult to interpret in any individual worker because of the relatively large technical variability often encountered in spirometry testing. Despite this variability, to protect lung health among workers with diseases that develop rapidly, clinicians may need to identify individuals who may have experienced declines in FEV 1 over shorter time periods (months to a few years) (87, 88) .
The most practical thresholds for clinicians to use in comparing longitudinal FEV 1 measurements are based on a 15% loss from baseline, taking into account expected age-related loss. ATS recommends that a decline of 15% or more over a year in otherwise healthy individuals be called "significant," beyond what would be expected from typical variability (3). A threshold of 15% decline in FEV 1 from baseline to follow up for longer periods of time, beyond the expected loss due to aging during the follow-up period, has been recommended by NIOSH to monitor coal miners (89) , and by ACOEM (5, 6) . Some caution in interpretation of early changes in coal miners has been advised, because initial rapid decline in FEV 1 , primarily in the first year of work, may be transient, possibly due to inflammatory changes (90) (91) (92) . Table 3 shows two methods to calculate a 15% decline in FEV 1 beyond expected aging: a percent predicted method and a volume method. Although not identical, they provide very similar thresholds for excessive decline in FEV 1 . This 15% approach detects smaller annual percent declines in FEV 1 as excessive with more years of follow up (e.g., from 15% decline with 1 yr of follow up to 4% annual decline with 5 yr of follow up) (82) . These thresholds are similar to the threshold FEV 1 decline determined by more complicated computerized approaches (described below) when within-person testing variability is about 6%) (Figure 1 ). For diseases that develop rapidly, declines in FEV 1 of less than 15% over shorter time periods may be clinically important (87, 93) .
Computerized approaches using linear regression or calculating lower limit of longitudinal decline (LLD) have also been used to evaluate longitudinal spirometry data in individuals and groups of workers (program data) ( Table 3 and Figure 1 ) (60, 82, 94) . Computer approaches can evaluate individual and group withinperson variation (program data precision), and calculate a threshold FEV 1 LLD based upon the actual data precision (82) . Studies using LLD have shown that the approach provides high clinical utility (specificity) in recognizing excessive FEV 1 decline in several working populations, (e.g., firefighters, pulp paper mill workers, and construction workers) (60) . When this method is used, it is most useful during the initial years (up to 5-8 yr) of follow up, when testing variability limits the interpretation of smaller changes in FEV 1 (60, 82) . As noted, the 15% (plus expected aging) threshold for FEV 1 assumes a within-person variation of about 6% (82). Higher quality spirometry programs can have less variability (e.g., 3-5%), and may be more reliable in identifying smaller declines in FEV 1 (e.g., 8-10%) as being excessive during the initial years of follow up (Figure 1) (20, 60, 82) . Thus, highquality spirometry programs with better data precision can enhance the clinician's Figure 1 . Threshold rates of FEV 1 loss that can be considered excessive based on different approaches to identify excessive FEV 1 volume loss. Examples based on (A) a 50-year-old white man (70 inches tall with a baseline FEV 1 of 3.93 L) and (B) a 50-year-old white woman (64 inches tall with baseline FEV 1 of 2.81 L). The rates of decline in FEV 1 (ml/yr) that can be considered excessive based on using several methods described in Table 3 to identify excessive threshold values of FEV 1 decline are shown for each example. The method based on a 15% threshold FEV 1 loss (plus aging-related FEV 1 decline) is as described in Table 3 . The limit of longitudinal decline (LLD), recommended for use over the first 8 years of follow up, is shown at three different levels of spirometry program quality, estimated by within-person variation in FEV 1 (6%, less precision; 5%, better precision; 4%, even better precision). For all methods, the rate of FEV 1 decline that can be identified as excessive decreases as the years of follow up increase. Similar thresholds for FEV 1 decline are obtained using the 15% method as the computerized LLD approach when testing variability is about 6%. With better-quality spirometry (4 and 5% variation), the LLD method identifies lower rates of FEV 1 decline as excessive. Rate of decline determined using linear regression (by calculating the individual's observed rate of FEV 1 decline [ml/yr] using all available acceptable spirometry results) is not shown. Also shown are three rates of annual decline discussed in the text: 30 ml/yr (typical average annual decline), and two higher rates associated with increased morbidity and mortality in long-term epidemiology studies (50 and 90 ml/yr).
ability to identify individuals who are experiencing excessive declines.
After follow-ups of more than 5-8 years, the rate of lung function decline can be reliably estimated by linear regression, using all of the person's observed FEV 1 data over time (82) . Because FEV 1 decline is not always linear, data should be inspected to assure that a linear model is appropriate. Although a specific action level for rate of decline has not been established and is difficult to apply to an individual, the typical rate of decline in FEV 1 in nonsmokers is about 29 ml/yr. Accelerated rates of decline (.60-90 ml/yr on average) have been associated with increased morbidity and mortality, as noted previously here.
Some computer approaches can also identify excessive variability and other measures of program quality in groups under surveillance, which may reflect either correctable technical issues in performing spirometry or increased burden of disease, potentially related to work exposures (20, 82, 95) .
Recommendation
Spirometry measurements should be evaluated relative to workers' baseline or prior tests, in addition to comparing to population normal ranges. This is particularly important when baseline measurements exceed predicted values. FEV 1 decline over time should be evaluated using one or more of the approaches described, and interpreted in the context of worker exposures, symptoms, and other clinical information.
Action Plan for Spirometry in the Work Setting
The key components of a workplace spirometry program should be supervised by the clinician responsible for performing spirometry testing (Table 1) . Groups eligible for spirometry monitoring should be defined based upon the potential respiratory hazards. The specific reason(s) spirometry is being performed should be clear, including the exposures of concern, which may dictate the frequency and/or timing of testing. Spirometry can be part of the medical evaluation for respirator use, in which case the employer should have a complete written respiratory protection program (96, 97) . The "action levels" that will be considered abnormal and trigger further evaluation need to be established, as well as a plan for when action levels are exceeded. Responsibilities for evaluation of both the individual and group spirometry and other health and workplace data should be clarified. Lines of communication should be established between the provider, worker, and employer that enable communication of relevant information, and also maintain confidentiality of medical information.
The results of spirometry performed in the work setting require careful interpretation (Table 4) . Clinicians involved should be familiar with the performance and interpretation of spirometry, and should have knowledge of the work exposures of concern. To protect worker Definition of abbreviations: CT = computerized tomography; LLD = limit of longitudinal decline; LLN = lower limit of normal; PFTs = pulmonary function tests. 
AMERICAN THORACIC SOCIETY DOCUMENTS
confidentiality, providers must not disclose individual workers' personal health information to employers without employee consent.
The technical quality of spirometry testing and accuracy of demographic information should always be reviewed. Consider repeat testing if tests are invalid; lack of repeatability, in particular, may indicate disease. The measured values from spirometry should be compared with predicted reference values, and levels below LLN identified. Current spirometry results should be compared with available prior testing, even if above the LLN. Excessive decline in FEV 1 should be determined using one of the approaches discussed here (Table 3) . Workers with values below the LLN and/or an excessive decline in FEV 1 should be further evaluated for potential causes and preventable risk factors. Factors such as work exposures, respiratory symptoms, and medical information (e.g., diagnoses, medications) should always also be considered, as spirometry values or rates of decline can remain "normal" when other factors may indicate that further evaluation is needed.
The specific steps to be taken will depend on several considerations, including the exposures of concern, the magnitude of the lung function abnormality and/or decline over time, and the clinical context (Table 5) . A careful occupational history, including workplace exposures and workrelated symptoms, should be obtained, and baseline/follow-up questionnaires should be reviewed. Further workup may include more complete pulmonary function testing (e.g., lung volumes, diffusing capacity) and chest imaging (radiographs, computerized tomography scan). Detailed algorithms and guidelines exist for specific work-related pulmonary diseases, and are beyond the scope of this article (98) (99) (100) . Appropriate interventions could include improved administrative or engineering controls to reduce exposures, termination of implicated occupational exposures, smoking cessation, and/or treatment of medical conditions, such as asthma.
In addition to management of the individual worker, the analysis of aggregate worker data (from the same workplace, company, job, or industry), both cross-sectional and longitudinal, can offer significant benefit. Spirometry, questionnaire, other health data, and exposure and job information can be linked for further evaluation while also being de-identified to protect individual worker privacy. Associations can be identified between work factors (exposures, job tasks, work locations) and lung function, which can easily be missed when reviewing workers individually, helping to target preventive efforts, such as reduction of potentially hazardous exposures. Such analysis can also help employers assess the effectiveness of current workplace preventive measures and better focus further preventive efforts. The distribution of individuals with spirometry abnormalities by job category, location, and/or task should be evaluated. Although additional expertise and support from the employer is needed for more complex aggregate analysis of spirometry and other available data, such analysis is strongly encouraged, as it may permit identification and control of exposurerelated health problems. The computerization of medical and workplace data should greatly facilitate such aggregate data analysis. n
